Vanguard Group Inc Clarus Therapeutics Holdings, Inc. Transaction History

Vanguard Group Inc

  • $5.46 Trillion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$0.02 - $0.22 $20,782 - $228,612
-1,039,148 Closed
0 $0
Q2 2022

Aug 12, 2022
BUY
N/A
864,648 Added 495.5%
1,039,148 $397,000
Q1 2022

May 13, 2022
BUY
N/A
7,900 Added 4.74%
174,500 $260,000
Q4 2021

Feb 14, 2022
BUY
N/A
166,600 New
166,600 $405,000

About Clarus Therapeutics Holdings, Inc.

CRXT Quotes by TradingView
  • Ticker CRXT
  • Exchange NASDAQ
  • Shares Outstandng 52,020,700
  • Market Cap $652
  • Description
  • Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for pr...
More about CRXT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email